Q4 FY2024 · ended Dec 31, 2024 · Revenue $1,000, -99.8% YoY · Filed Mar 13, 2026
Ernexa Therapeutics Inc. (ERNA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$4.2 million. As of Jun 30, 2026 it held $5.0 million in cash and investments and $349,000 in total debt.
Revenue
$1,000
-99.8% vs prior quarter
Net income
$-4.01M
-27.7% vs year-ago quarter
Operating cash flow
$-4.15M
-64.0% vs year-ago quarter
Free cash flow
$-4.16M
-83.4% vs prior quarter
EPS
$-3.40
+77.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.63M
-78.7% vs year-ago quarter
Net cash
$4.68M
Q2 FY2026
Operating margin
-269700.0%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERNA (Nasdaq), ERNAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc. (until Apr 4, 2025); Brooklyn ImmunoTherapeutics, Inc. (until Oct 14, 2022); NTN BUZZTIME INC (until Mar 23, 2021); NTN COMMUNICATIONS INC (until Dec 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.1M | -$5.6M | -$2.1M | -$2.0M | -$2.5M |
| Net income | -$4.0M | -$5.5M | -$1.5M | -$1.2M | -$3.1M |
| Diluted EPS | -$3.40 | -$6.95 | -$0.18 | -$0.15 | -$15.19 |
| Operating cash flow | -$4.2M | -$2.3M | -$1.1M | -$1.3M | -$2.5M |
| Free cash flow | -$4.2M | -$2.3M | -$1.2M | -$1.6M | — |
| Total assets | $6.3M | $10.5M | $5.8M | $6.2M | $7.6M |
| Total liabilities | $3.1M | $3.7M | $3.4M | $2.6M | $3.1M |
| Stockholders' equity | $3.2M | $6.9M | $2.4M | $3.6M | $4.4M |
| Cash and investments | $5.0M | $9.2M | $1.9M | $3.0M | $4.3M |
| Total debt | $349,000 | $389,000 | $490,000 | $552,000 | $593,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jul 1, 2026 |
All 1000 Ernexa Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.